Shilpa Medicare to hold 38th AGM on September 23, 2025 via VC/OAVM
The AGM announcement and proposed resolutions, including director appointments, remuneration approvals, and bonus share issuance, have a moderate impact on the company's governance and shareholder value.
The announcement includes positive elements such as dividend declaration, re-appointments of key personnel, and the issuance of bonus shares, which are generally perceived favorably by investors.
* Shilpa Medicare Limited will hold its 38th Annual General Meeting (AGM) on Tuesday, September 23, 2025, at 11:00 a.m. (IST) through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). * The notice of the 38th AGM and the Annual Report for the financial year 2024–25 are available on the Company’s website. * The agenda includes: * Adoption of audited standalone and consolidated financial statements for the year ended 31 March 2025. * Declaration of a dividend of ₹1 per equity share for the financial year ended March 31, 2025. * Re-appointment of Mr. Sharath Reddy Kalakota as a Whole Time Director for 5 years w.e.f. October 1, 2025, with a remuneration of ₹16,62,662 per month. * Appointment of Mr. Ashraf Loutfy Abdelhamid Allam as an Independent Director for a term of 2 years with a remuneration of ₹35,00,000 per annum. * Re-appointment of Dr. Anita Bandyopadhyay as a Women Independent Director for a further period of 3 years with a remuneration of ₹18,00,000 per annum. * Revision in remuneration of Mr. Keshav Bhutada as Executive Director & CEO of Shilpa Pharma Lifesciences Ltd (SPLL) to ₹1.00 crore per annum plus 1% commission on SPLL's profits. * Appointment of Mr. D.S Rao as Secretarial Auditors for 5 years. * Issue of bonus shares by capitalizing up to ₹9,77,90,908 out of securities premium.
What to do with a filing like this
Shilpa Medicare Limited filed this with the NSE as a statutory disclosure, categorised under agm-egm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shilpa Medicare Limited. Read the original for the full detail.